Healthcare
Rafarma Pharmaceuticals, Inc.(RAFA)
Live Price
Offline$0.047
-6.00% today
1Y Change
-38.18%
Window
Jun 23, 2025 → Jun 5, 2026
- Market Cap
- $10.00M
- Revenue Growth
- +1.1%
- EPS Growth
- +33.3%
- Dividend Yield
- 0.0%
Coverage: 240 bars · Jun 23, 2025 → Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rafarma Pharmaceuticals, Inc. (RAFA) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.05 and down 38.2% across the available one-year price window (Jun 23, 2025 → Jun 5, 2026). Baseline metrics include revenue growth of +1.1%, EPS growth of +33.3%, a dividend yield of 0.0%. What stands out right now is revenue +1.1%, EPS +33.3%, free cash flow 0.0% with operating margin 4.1% and ROIC 2.4%. Valuation is more restrained than many high-expectation growth names at P/E 25.0 and price/sales 0.6. Stock Foundry combines RAFA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+1.1% vs +7.6% peer median
Operating Margin
Below sector median
+4.1% vs +19.4% peer median
P/E
Below sector median
25.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +1.1% and EPS at +33.3%, with operating margin around 4.1%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RAFA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RAFA Max Drawdown
-72.73%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RAFA and SPY.
Company Overview
Rafarma Pharmaceuticals, Inc.
Other OTC
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
- Leadership
- Sergey Brusnitsin
- IPO Date
- Dec 11, 2012
- Employees
- 700
- Street Address
- 49 West 9000 South
- Mailing
- Sandy, UT, 84070
- Region
- Sandy, UT, US
- Reporting Currency
- USD
- Investor Line
- 801-210-7135
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 25.0
- EV/EBITDA
- 17.4
- Price/Sales
- 0.6
- Price/Book
- 0.5
Growth
- Revenue
- +1.1%
- EPS
- +33.3%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 6.4%
- Operating Margin
- 4.1%
- Net Margin
- 2.5%
- ROE
- 2.1%
- ROIC
- 2.4%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 1.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.